bms-986012 + nivolumab

BMS-986012 is a first-in-class, fully human IgG1 monoclonal antibody that targets fucosyl-GM1 (Fuc-GM1), a glycolipid highly expressed on small cell lung cancer (SCLC) cells. It mediates anti-tumor effects through antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cellular phagocytosis[1][3]. Nivolumab is a programmed death 1 (PD‑1) immune checkpoint inhibitor monoclonal antibody that enhances T-cell mediated anti-tumor responses. The combination of BMS‑986012 and nivolumab has been investigated in relapsed/refractory and extensive-stage SCLC, both as monotherapy and in combination with chemotherapy. Clinical trials have shown the regimen to be well tolerated with promising signals of improved overall survival compared to standard regimens[2][3][7]. Bristol Myers Squibb is developing this combination; a fixed-dose combo formulation (BMS‑986489) is also under investigation in phase 3 trials for first-line treatment of extensive-stage SCLC[6].

Other names

bms-986012 + opdivo